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Abstract
 
The role of CD40 ligand (CD40L)/CD40 signaling in T cell–dependent B cell differentiation
and maturation has been amply documented. The mechanism of CD40 signaling in B cells has
been well established, whereas the signaling mechanism of CD40L in T cell costimulation remains
unknown. In this study we show that CD28i, a transmembrane splice variant of CD28 costim-
ulatory receptor, complexes with CD40L in human T cells. The cross-linking of CD40L resulted
in the coendocytosis of CD28i with CD40L. The tyrosine phosphorylation of CD28i followed
the cross-linking of CD40L, and the overexpression of CD28i augmented the c-Jun NH
 
2
 
-
terminal kinase, p21-activated kinase 2, and nuclear factor 
 
 
 
B activation. These data indicate
that CD28i, by functioning as a signaling adaptor, transduces CD40L signaling as well as CD28
signaling in human T cells.
Key words: CD40L • CD28 • CD28 variant • T cell costimulation
 
Introduction
 
Costimulation is a necessary requirement for T cells to
achieve maximal activation by TCR engagement with Ag–
MHC complexes. CD28 is a costimulatory receptor that
plays a central role in stimulating naive T cells (1). Upon acti-
vation, T cells express a greater repertoire of costimulatory
receptors including TNF receptor family 4-1BB, OX-40
(2, 3), the immunoglobulin family (CD28 and ICOS; refer-
ence 4), and TNF ligand family receptors (CD40 ligand
[CD40L], FasL, and LIGHT; references 5–7). CD40L is a
type II transmembrane protein of which interaction with
CD40 on B cells triggers important signals for B cell differ-
entiation, maturation, and apoptosis (5). The interaction of
CD40L with CD40 expressed on APCs, such as macro-
phages and dendritic cells, promotes cell maturation and
cytokine production (IL-12), which subsequently regulates
the cell-mediated immunity by increasing Th1-type helper
cell differentiation (8). Conversely, cross-linking of CD40L
costimulates T cells, promoting secretion of many cyto-
kines including IL-4, IL-10, interferon-
 
 
 
, and TNF-
 
  
 
(9).
CD40L-deficient mice demonstrated that CD40L signaling
is necessary for Ag-specific priming of CD4 T cells and neg-
ative selection of self-reactive T cells during thymic devel-
opment (10, 11). The cytoplasmic tail of CD40L is 22
amino acids long and it lacks of known enzymatic activity
(12). CD40L activates c-Jun NH
 
2
 
-terminal kinase (JNK)/
p38 kinase, neutral sphingomyelinase, and protein kinase C
(PKC) in human and murine T cells (13–15). Despite the
compelling evidence of CD40L signaling in T cells, the
proximal signaling mechanism of CD40L is not known.
We have previously characterized CD28i, which is one of
several human CD28 splice variants (16–19). CD28i is
unique among other isoforms as it retains an intact trans-
membrane region and cytoplasmic tail, but lacks the B7
ligand binding motif (16). CD28i associates with wild-type
CD28 and cross-linking of CD28 transactivates CD28i. In
this study, CD28i in CD40L
 
  
 
T cells was investigated. Our
data indicates that CD28i is a novel signaling adaptor protein
that transduces and augments CD40L-mediated signaling.
 
Materials and Methods
 
Construction of Expression Vectors.
 
CD28i was modulated with
enhanced green fluorescent protein (EGFP; CLONTECH Labora-
tories, Inc.) or with hemophilus influenza hemagglutinin (HA)
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tag as previously described (16). HA-tagged CD28i (CD28i-HA)
was subcloned into pcDNA3.1 (CLONTECH Laboratories,
Inc.) or pBIG2i (20). Human CD40L cDNA was isolated by
RT-PCR from thymocyte total RNA (CLONTECH Laborato-
ries, Inc.) and subcloned into pcDNA3.1.
 
Detection of CD28, CD40L, CD28i, and Phosphotyrosine.
 
The Abs specific for human CD28 (L293; BD Biosciences), hu-
man CD28 COOH-terminal (sc-1623; Santa Cruz Biotechnol-
ogy, Inc.), human CD40L (sc-978, sc-9097; Santa Cruz Biotech-
nology, Inc. and CSA-186; StressGen Biotechnologies), and
HA-tag (3F10; Roche and F-7; Santa Cruz Biotechnology, Inc.)
were used. Cell extracts were prepared using lysis buffer contain-
ing 1% Nonidet P-40 (BDH Chemicals) or 1% digitonin (Sigma-
Aldrich; reference 21). To immunoprecipitate CD28i-HA with
anti-HA Ab (rat IgG1), protein A/G agarose and protein L aga-
rose bead cocktail (sc-2336; Santa Cruz Biotechnology, Inc.)
were used.
 
Assay of JNK, p21-activated Kinase (PAK), and Akt Activation in
CD40L-stimulated D1.1 Transfectant Cells.
 
Rabbit Abs specific
for JNK, PAK, Akt, phospho-SAPK/JNK (Thr183/Tyr185),
phospho-PAK1 (Ser144)/PAK2 (Ser141)/PAK3 (Ser139), and
mouse Ab (587F11) specific for phospho-Akt (Ser473) were
purchased from Cell Signaling Technology. D1.1 transfectant
cells harboring inducible CD28i-HA were incubated with 0.5
 
 
 
g/ml doxicyclin for 48 h. Cells were then serum starved for
6 h before being stimulated with 2 
 
 
 
g/ml anti-CD40L Ab.
Whole cell lysates (5 
 
  
 
10
 
4 
 
cell-derived 1% Nonidet P-40 ex-
tracts) were analyzed by Western blotting (16). Western blot-
ting specific for each phosphor protein was performed first and
then assay membrane was reproved with JNK, PAK, or Akt-
specific Abs.
 
Laser Confocal Microscopy.
 
CD28i-EGFP (16) was transfected
into D1.1 cells by electroporation (300 V, 800 
 
 
 
F; Bio-Rad Lab-
oratories). Cells were then incubated at 37
 
 
 
C overnight and
stained with PE-conjugated Abs specific for CD40L, CD28,
CD2, or CD3 (BD Biosciences) before confocal microscopy. To
detect coendocytosis of CD40L and CD28i, CD28i-EGFP–
transfected D1.1 cells were incubated with PE anti-CD40L Ab
(TRAP1; BD Biosciences) for 30 min at 37
 
 
 
C.
 
Nuclear Factor (NF)-
 
 
 
B and IL-2 Promoter Reporter Assays.
 
HEK293 cells were transfected with pcDNA3.1 harboring
CD28i-HA and human CD40L using DEAE-dextran (16). The
NF-
 
 
 
B reporter plasmid (
 
 
 
B-Luc
 
; reference 22) or IL-2 pro-
moter reporter plasmid (
 
IL-2-luc
 
; reference 23) were also trans-
fected to HEK293 simultaneously or to D1.1 cells. After over-
night culture at 37
 
 
 
C, cells were stimulated with anti-CD40L
Ab for 6 h to perform NF-
 
 
 
B reporter luciferase assay (Pro-
mega). To assay IL-2 promoter activity, cells were stimulated
with 10 ng/ml PMA plus 10 
 
 
 
g/ml PHA for 8 h in the pres-
ence of 2 
 
 
 
g/ml anti-CD40L Ab or 2 
 
 
 
g/ml anti-CD28 Ab.
CD40L-specific goat Ab or CD28-specific mouse Ab was fur-
ther cross-linked at the same time with 10 
 
 
 
g/ml anti–goat IgG
Ab or anti–mouse IgG Ab, respectively, and then the prepared
cell lysates were subjected to the luciferase assay. Data represent
fold increase compared with nonstimulated cell response for
NF-
 
 
 
B reporter assay or the PMA plus PHA response for IL-2
promoter reporter assay.
 
Figure 1.
 
(a) The colocalization of CD28i with CD40L monitored by
confocal microscopy. CD40L
 
  
 
Jurkat cell subline, D1.1 cell, was trans-
fected with EGFP or CD28i-EGFP as indicated. In A, cells were surface
stained with PE anti-CD40L Ab, PE anti-CD28 Ab, PE anti-CD2 Ab, or
PE anti-CD3 as indicated below. In B, green fluorescence by EGFP or
CD28i-EGFP expression was shown. In C, green fluorescence and red
fluorescence were merged. (b) Anti-CD40L Ab induced coendocytosis of
CD40L and CD28i. D1.1 cell was transfected with CD28i-GFP and
incubated with PE anti-CD40L Ab at 37
 
 
 
C (top) or 4
 
 
 
C (bottom) for 30
min. Then cells were assayed by confocal microscopy. In panel a, CD40L
and CD28i are merged. The magnified views of coendocytosis or control
are shown in panel b. Panel c shows CD40L and panel d shows CD28i-
EGFP staining. 
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Results and Discussion
 
CD28i Colocalizes with CD40L in CD40L
 
  
 
D1.1 Cells.
 
We investigated whether CD28i can associate with trans-
membrane receptors other than CD28. When examined
by confocal microscopy, we found that CD28i-EGFP
colocalizes with CD40L in the CD40L
 
  
 
D1.1 Jurkat
subline (Fig. 1 a). In parallel, we also tested CD2, CD3,
and CD43, but none of these receptors colocalized with
CD28i in this cell line (only CD2 and CD3 are shown in
Fig. 1 a).
 
CD40L Cross-linking Induces Coendocytosis of CD28i and
CD40L.
 
To test a possibility of CD28i playing a role in
CD40L signaling, we investigated whether the cross-link-
ing of CD40L could stimulate endocytosis (24) that in-
cluded both CD40L and CD28i. When D1.1 cells were
transfected with CD28i-EGFP and stimulated with PE
anti-CD40L Ab, we observed yellow cytoplasmic vesicles
indicating green and red fluorescence cointernalization
(Fig. 1 b). The data provide evidence that CD40L and
CD28i functionally/physically associate.
 
CD40L Coimmunoprecipitates with CD28i.
 
To deter-
mine if CD40L and CD28i associate biochemically, we es-
tablished a stable transfectant of D1.1 that expressed CD28i-
HA. When characterizing the transfectant by performing
CD40L-specific Ab or HA-specific Ab immunoprecipi-
tation and Western blotting using anti-HA Ab or anti-
CD40L Ab, we found that CD40L and CD28i-HA coim-
munoprecipitated from 1% digitonin buffer cell extracts
(Fig. 2, a and b), in which weakly associated receptor com-
plex can be retained (25). Similarly to what we observed in
our previous study of the CD28 and CD28i complex (16),
CD40L was not coimmunoprecipitated with CD28i from
1% Nonidet P-40 cell extracts, in which weakly associ-
Figure 2. Coimmunoprecipitation of CD28i with
CD40L from 1% digitonin cell extracts. (a) Cell extracts
from CD28i-HA–transfected D1.1 cells were prepared
using 1% digitonin buffer and immunoprecipitated with
anti-CD40L Ab, anti-CD28 Ab, or isotype control Ab.
Immunoprecipitates were fractionated by SDS-PAGE.
Western blot membranes were probed with anti-HA Ab.
(b) The same extracts were immunoprecipitated with anti-
HA Ab, anti-CD40L Ab, or isotype control Ab, and fraction-
ated by SDS-PAGE. Subsequently, the CD40L-specific
Western blotting was performed. (c and d) 1% digitonin
cell extracts from 72-h PHA blasts of peripheral blood
mononuclear cells were immunoprecipitated by CD28- or
CD40L-specific Abs and then characterized by Western
blotting specific to CD28 COOH terminus (c) (reference
16) or CD40L (d). Specific Abs and isotype control Ab
used for immunoprecipitation were indicated under each
lane. In b, the bracket shows the doublet of CD40L (refer-
ence 30). C-terminal in the figure stands for CD28
COOH terminus–specific Ab. Filled arrows indicate
CD28i-HA in a, CD40L in b and d, and CD28i in c. H, Ig
heavy chain; L, Ig light chain. 
Modulation of CD40L Signaling by CD28 Variant
 
1028
ated receptor components dismembered. Thus, CD28i and
CD40L form a weakly assembled complex in D1.1 cells.
To demonstrate the CD40L–CD28i complex in normal
cells, we prepared PHA blasts from human peripheral
blood mononuclear cells. Cells were lysed by 1% digitonin
buffer and immunoprecipitated by CD40L or CD28 cyto-
plasmic tail-specific Abs. This experiment showed that the
complex of CD40L and CD28i existed in normal T cell
 
Figure 3.
 
(a) Tyrosine phosphorylation of CD28i induced by CD40L
stimulation. CD28-HA–transfected D1.1 cells were serum starved for 6 h
and incubated with anti-CD40L Ab for 30 min on ice. Anti–goat IgG was
added to start stimulation at 37
 
 
 
C for 2, 5, and 10 min. Nonidet P-40 cell
lysates of the stimulated cells were immunoprecipitated with anti-HA Ab.
Immunoprecipitates were analyzed on Western blots. The top panel was
blotted with anti-Phosphotyrosine (RC20; indicated as p-Tyr). The same
membrane was reprobed with anti-HA Ab (indicated as CD28i-HA). L, Ig
light chain; lane 1, nonstimulated control; lane 2, CD40L stimulated for 2
min; lane 3, CD40L stimulated for 5 min; lane 4, CD40L stimulated for 10
min. (b) Induction of CD28i-HA expression by doxicyclin in D1.1
transfectant cells. CD28i-HA (
 
 
 
23 kD) was expressed in D1.1 cells by
doxicyclin-inducible promoter and whole cell lysates were assayed by
HA-specific Western blotting. (
 
 
 
), doxicyclin-nontreated cells; (
 
 
 
),
doxicyclin-treated cells (0.5 
 
 
 
g/ml for 48 h). (c) Overexpression of CD28i-
HA enhances the activation of JNK and PAK2 in CD40L-stimulated
D1.1 cells. Cells were stimulated with anti-CD40L Ab for periods of time
indicated on top. Whole cell lysates were characterized with Western blotting
specific for active-form JNK (represented by p46), PAK2 (
 
 
 
64 kD), or
Akt (
 
 
 
60 kD), and indicated as pJNK, pPAK2, and pAkt on the left of
each panel. To measure the level of proteins, the assay membranes were re-
probed with JNK-, PAK-, or Akt-specific Abs and indicated as JNK,
PAK2, or Akt on the left of each panel. Dox (
 
 
 
), cells not treated with
doxicyclin; Dox (
 
 
 
), cells treated with doxicyclin.
Figure 4. (a) Enhanced induc-
tion of NF- B activation by
CD40L cross-linking in CD28i-
HA–overexpressing D1.1 cells.
CD28i-HA–induced (48 h) or
–noninduced  D1.1 cell was
loaded with NF- B reporter
plasmid. Cells were stimulated
with anti-CD40L Ab for 6 h and
then the cell extracts were
measured for NF- B activity by
luciferase assay. Results are rep-
resentative of three experiments.
Data are the average of triplicate
cultures with SDs. (b) Enhanced
induction of NF- B activation
by CD40L cross-linking in
HEK293 CD28i-HA transfec-
tant cells. HEK293 cells were
transfected with CD28i and
CD40L, and were loaded with
NF- B reporter plasmid. Cells
were stimulated with anti-CD40L
Ab for 6 h and then the cell ex-
tracts were measured for NF- B
activity by luciferase assay. Results
are representative of two experi-
ments. Data are the average of
triplicate cultures with SDs. 
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Figure 5. Poor induction of IL-2 promoter activity by cross-linking CD40L in D1.1 transfectant cells. CD28i-HA was induced (48 h) in D1.1 trans-
fectant cells with doxicyclin treatment. Cells were loaded with an IL-2 promoter reporter plasmid for 6 h. Cells were then stimulated with PHA plus
PMA in the presence of anti-CD40L Ab or anti-CD28 Ab for 6 h. Cell extracts were assayed for IL-2 promoter activity by luciferase assays. Results are
representative of three experiments. Data are the average of triplicate cultures with SDs.
 
mitogen blasts (Fig. 2, c and d). In addition, the assay re-
vealed that wild-type CD28 (
 
 
 
44 kD) was not in associa-
tion with CD40L (Fig. 2 c).
 
Cross-linking of CD40L Induces CD28i Tyrosine Phosphor-
ylation.
 
When D1.1 was incubated with anti-CD40L Ab,
the cross-linking of CD40L resulted in the transient tyro-
sine phosphorylation of CD28i-HA (Fig. 3 a). The data
suggests that CD40L transactivates CD28i in T cells by in-
ducing tyrosine phosphorylation.
 
Expression of CD28i Enhances JNK and PAK2 Activation
Induced by CD40L.
 
CD40L signaling was shown to acti-
vate JNK/p38MAP kinase, sphingomyelinase, and PKC
(13–15). PAK, p21-activated kinase, was also activated by
CD28 signaling (21). Therefore, we investigated if the in-
creased expression of CD28i alters the activities of these
known kinases in CD40L-stimulated D1.1 cells. We used
D1.1 transfectant in which CD28i-HA expression was in-
ducible by doxicyclin (Fig. 3 b), but it did not alter CD40L
expression levels (unpublished data). The expression of
CD28i-HA in this transfectant cell in the absence of doxicy-
clin was at a nearly undetectable level. As shown in Fig. 3 c,
the stimulation with CD40L-specific Ab significantly in-
creased JNK phosphorylation in noninduced cells, which
indicated JNK activation and confirmed the previously re-
ported observation (13). When doxicyclin-treated D1.1
transfectant was tested, the expression of phosphorylated
JNK increased in a greater extent than that observed in doxi-
cyclin-nontreated cells. Thus, JNK activation induced by
CD40L stimulation was enhanced by the increased expres-
sion of CD28i-HA. We also found that CD40L stimulation
activated PAK2 (
 
 
 
64 kD) in both CD28i-HA–induced and
–noninduced cells in 2–5 min. Nevertheless, PAK2 activa-
tion occurred in greater extent in doxicyclin-treated cells.
Interestingly, neither PAK1 nor PAK3 was significantly ac-
tivated by the stimulation of CD40L (unpublished data).
One mechanism by which CD28i and CD40L interactions
could enhance CD40L signaling might be enhancing the fo-
cal adhesion-like structure within T cells at T cell to B7
 
 
 
APC binding sites via clustering a greater number of CD28-
derived cytoplasmic tails as it was reported for CD28 (26).
The enhanced activation of the PAK2-JNK pathway (Fig. 3
c) seems to support this possibility because it overlaps with
Rac1, Cdc42-induced F-actin formation/cytoskeleton re-
organization pathway (21, 26). The presence of CD28i may
enhance the molecular mechanisms that contribute in estab-
lishing the immunological synapse (27) essential for the T
cell costimulation. Finally, our study showed a weak induc-
tion of Akt activation in noninduced cells (Fig. 3 c). The
activation of Akt was not detected in CD28i-HA–induced
D1.1 cells by CD40L stimulation. The biological signifi-
cance of this observation is not clear.
 
Expression of CD28i Increases the Activation of CD40L-
induced NF-
 
 
 
B Stimulation.
 
Previous studies indicated that
CD40L stimulation activates PKC, which potentially acti-
vates NF-
 
 
 
B (15). Therefore, we extended our study by as-
saying NF-
 
 
 
B activity in CD40L-stimulated D1.1 transfec-
tant cells expressing CD28i-HA. The induction of NF-
 
 
 
B
reporter activity was significantly enhanced in CD28i-HA– 
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induced cells in comparison to that observed in noninduced
cells (Fig. 4 a). Thus, it is indicated that CD40L activates NF-
 
 
 
B and the presence of CD28i enhances this signaling. To
understand the interaction of CD40L and CD28i under a
more critical setting in which wild-type CD28 is absent, we
have investigated HEK293 (CD28
 
 
 
) cells transfected with
CD40L and CD28i using NF-
 
 
 
B reporter assay (Fig. 4 b).
The dual transfection of CD40L and CD28i into HEK293
cells resulted in 
 
 
 
30% CD40L
 
  
 
CD28i
 
  
 
cells in which
CD40L and CD28i-GFP colocalized (unpublished data). The
study demonstrated that anti-CD40L Ab-induced NF-
 
 
 
B ac-
tivation is CD28 independent and up-regulated by the pres-
ence of CD28i. Additional signaling mechanism that may re-
sult from trans-stimulating CD28i cytoplasmic tail by CD40L
could be YMNM motif-mediated survival signaling via PI3
kinase/NF-
 
 
 
B pathway (28). To verify this possibility, how-
ever, we may need additional study relevant to the PKC
pathway as we found that Akt is not activated by CD40L
stimulation in CD28i-HA–overexpressing D1.1 cells.
 
Study of IL-2 Promoter Activity in D1.1 Transfectant Cells
Stimulated by CD40L.
 
Finally, we investigated whether the
stimulation of CD40L augmented IL-2 promoter activity in
CD28i-HA–induced D1.1 cells. The experiments showed
only a modest augmentation of IL-2 promoter activity by the
increased expression of CD28i-HA (Fig. 5). The stimulation
of CD28 in the same cell efficiently induced IL-2 promoter
activity, confirming our previous observation (16). A recent
study showing that CD40L is not efficient in promoting IL-2
production in human PBL-T cells (29) supports our present
findings. Accordingly, the association of CD28i does not sim-
ply combine the CD28 cytoplasmic tail signaling to CD40L,
but selectively imparts CD28i-specific signaling activities,
such as PAK2 activation, to CD40L stimulation. The differ-
ence in the effects CD28i plays on CD40L may result from a
loose association between CD28i and CD40L, where the sig-
nal is not strong enough to activate IL-2 promoter. Alterna-
tively, CD40L may transduce a signal via its own cytoplasmic
tail or additional signaling adaptor molecules, and the cumu-
lative signaling does not support IL-2 promoter activation.
In summary, this study identified CD40L as a new bind-
ing partner for CD28i. By increasing T cell adhesion with
APCs and/or by increasing NF-
 
 
 
B signaling, CD28i co-
clustering with CD28 and CD40L can function as a regula-
tor of the T cell activation threshold.
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